Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

A two-site survey of medical center personnel's willingness to share clinical data for research: implications for reproducible health NLP research.

Weng C, Friedman C, Rommel CA, Hurdle JF.

BMC Med Inform Decis Mak. 2019 Apr 4;19(Suppl 3):70. doi: 10.1186/s12911-019-0778-z.

2.

The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia.

Rommel C, Rösner S, Lother A, Barg M, Schwaderer M, Gilsbach R, Bömicke T, Schnick T, Mayer S, Doll S, Hesse M, Kretz O, Stiller B, Neumann FJ, Mann M, Krane M, Fleischmann BK, Ravens U, Hein L.

Circ Res. 2018 Aug 17;123(5):550-563. doi: 10.1161/CIRCRESAHA.118.313036.

PMID:
29930145
3.

Brain Trauma Foundation Guideline Compliance: Results of a Multidisciplinary, International Survey.

Hirschi R, Rommel C, Letsinger J, Nirula R, Hawryluk GWJ.

World Neurosurg. 2018 Aug;116:e399-e405. doi: 10.1016/j.wneu.2018.04.215. Epub 2018 May 9.

PMID:
29751187
4.

Should we have a guard against therapeutic nihilism for patients with severe traumatic brain injury?

Hirschi R, Rommel C, Hawryluk GWJ.

Neural Regen Res. 2017 Nov;12(11):1801-1803. doi: 10.4103/1673-5374.219037. No abstract available.

5.

DNA methylation signatures follow preformed chromatin compartments in cardiac myocytes.

Nothjunge S, Nührenberg TG, Grüning BA, Doppler SA, Preissl S, Schwaderer M, Rommel C, Krane M, Hein L, Gilsbach R.

Nat Commun. 2017 Nov 21;8(1):1667. doi: 10.1038/s41467-017-01724-9.

6.

The aggressiveness of neurotrauma practitioners and the influence of the IMPACT prognostic calculator.

Letsinger J, Rommel C, Hirschi R, Nirula R, Hawryluk GWJ.

PLoS One. 2017 Aug 23;12(8):e0183552. doi: 10.1371/journal.pone.0183552. eCollection 2017.

7.

Solving Interoperability in Translational Health. Perspectives of Students from the International Partnership in Health Informatics Education (IPHIE) 2016 Master Class.

Turner AM, Facelli JC, Jaspers M, Wetter T, Pfeifer D, Gatewood LC, Adam T, Li YC, Lin MC, Evans RS, Beukenhorst A, van Mens HJT, Tensen E, Bock C, Fendrich L, Seitz P, Suleder J, Aldelkhyyel R, Bridgeman K, Hu Z, Sattler A, Guo SY, Mohaimenul IMM, Anggraini Ningrum DN, Tung HR, Bian J, Plasek JM, Rommel C, Burke J, Sohih H.

Appl Clin Inform. 2017 Jun 20;8(2):651-659. doi: 10.4338/ACI-2017-01-CR-0012.

8.

Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload.

Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy-Ordonez EB, Zeeb M, Preissl S, Gilsbach R, Melchior-Becker A, Rylski B, Stoll M, Schaefer L, Beyersdorf F, Stiller B, Hein L.

J Mol Cell Cardiol. 2016 Dec;101:145-155. doi: 10.1016/j.yjmcc.2016.10.011. Epub 2016 Oct 24.

PMID:
27789290
9.

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.

Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M.

Oncotarget. 2016 Aug 23;7(34):55083-55097. doi: 10.18632/oncotarget.10397.

10.

Adrenergic Repression of the Epigenetic Reader MeCP2 Facilitates Cardiac Adaptation in Chronic Heart Failure.

Mayer SC, Gilsbach R, Preissl S, Monroy Ordonez EB, Schnick T, Beetz N, Lother A, Rommel C, Ihle H, Bugger H, Rühle F, Schrepper A, Schwarzer M, Heilmann C, Bönisch U, Gupta SK, Wilpert J, Kretz O, von Elverfeldt D, Orth J, Aktories K, Beyersdorf F, Bode C, Stiller B, Krüger M, Thum T, Doenst T, Stoll M, Hein L.

Circ Res. 2015 Sep 11;117(7):622-33. doi: 10.1161/CIRCRESAHA.115.306721. Epub 2015 Jul 20.

11.

The perils of meta-regression to identify clinical decision support system success factors.

Fillmore CL, Rommel CA, Welch BM, Zhang M, Kawamoto K.

J Biomed Inform. 2015 Aug;56:65-8. doi: 10.1016/j.jbi.2015.05.007. Epub 2015 May 18.

12.

Cell membrane topology analysis by RICM enables marker-free adhesion strength quantification.

Klein K, Rommel CE, Hirschfeld-Warneken VC, Spatz JP.

Biointerphases. 2013 Dec;8(1):28. doi: 10.1186/1559-4106-8-28. Epub 2013 Oct 28.

PMID:
24706147
13.

PI3K and cancer: lessons, challenges and opportunities.

Fruman DA, Rommel C.

Nat Rev Drug Discov. 2014 Feb;13(2):140-56. doi: 10.1038/nrd4204. Review.

14.

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL.

Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7.

15.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA.

J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28.

16.

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA.

Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1.

17.

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr.

Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21.

PMID:
23085766
18.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

19.

PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.

Fruman DA, Rommel C.

Cancer Discov. 2011 Dec;1(7):562-72. doi: 10.1158/2159-8290.CD-11-0249. Epub 2011 Nov 29. Review.

20.

Macroporous silicon chips for laterally resolved, multi-parametric analysis of epithelial barrier function.

Michaelis S, Rommel CE, Endell J, Göring P, Wehrspohn R, Steinem C, Janshoff A, Galla HJ, Wegener J.

Lab Chip. 2012 Jul 7;12(13):2329-36. doi: 10.1039/c2lc00026a. Epub 2012 Apr 20.

PMID:
22522671
21.

PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis.

Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, Firestein GS.

Am J Pathol. 2012 May;180(5):1906-16. doi: 10.1016/j.ajpath.2012.01.030. Epub 2012 Mar 17.

PMID:
22433439
22.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.

Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.

23.

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D.

Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912.

24.

Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis.

Cummings HE, Barbi J, Reville P, Oghumu S, Zorko N, Sarkar A, Keiser TL, Lu B, Rückle T, Varikuti S, Lezama-Davila C, Wewers MD, Whitacre C, Radzioch D, Rommel C, Seveau S, Satoskar AR.

Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1251-6. doi: 10.1073/pnas.1110339109. Epub 2012 Jan 9.

25.

Defining the role of TORC1/2 in multiple myeloma.

Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM.

Blood. 2011 Dec 22;118(26):6860-70. doi: 10.1182/blood-2011-03-342394. Epub 2011 Nov 1.

26.

Next-generation flow cytometry.

Janes MR, Rommel C.

Nat Biotechnol. 2011 Jul 11;29(7):602-4. doi: 10.1038/nbt.1919. No abstract available.

PMID:
21747386
27.

Simplified approach for quantitative digital holographic phase contrast imaging of living cells.

Kemper B, Vollmer A, Rommel CE, Schnekenburger J, von Bally G.

J Biomed Opt. 2011 Feb;16(2):026014. doi: 10.1117/1.3540674.

28.

Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays.

Kroll A, Dierker C, Rommel C, Hahn D, Wohlleben W, Schulze-Isfort C, Göbbert C, Voetz M, Hardinghaus F, Schnekenburger J.

Part Fibre Toxicol. 2011 Feb 23;8:9. doi: 10.1186/1743-8977-8-9.

29.

Contrast-enhanced digital holographic imaging of cellular structures by manipulating the intracellular refractive index.

Rommel CE, Dierker C, Schmidt L, Przibilla S, von Bally G, Kemper B, Schnekenburger J.

J Biomed Opt. 2010 Jul-Aug;15(4):041509. doi: 10.1117/1.3449567.

30.

Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases.

Rommel C.

Curr Top Microbiol Immunol. 2010;346:279-99. doi: 10.1007/82_2010_79. Review.

PMID:
20593311
31.

PI3K: from the bench to the clinic and back.

Vanhaesebroeck B, Vogt PK, Rommel C.

Curr Top Microbiol Immunol. 2010;347:1-19. doi: 10.1007/82_2010_65. Review.

32.

Chemical inducers and transcriptional markers of oligodendrocyte differentiation.

Joubert L, Foucault I, Sagot Y, Bernasconi L, Duval F, Alliod C, Frossard MJ, Pescini Gobert R, Curchod ML, Salvat C, Nichols A, Pouly S, Rommel C, Roach A, Hooft van Huijsduijnen R.

J Neurosci Res. 2010 Sep;88(12):2546-57. doi: 10.1002/jnr.22434.

PMID:
20544820
33.

The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.

Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, Williams RL.

Nat Chem Biol. 2010 Mar;6(3):244. No abstract available.

PMID:
20154668
34.

The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.

Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, Williams RL.

Nat Chem Biol. 2010 Feb;6(2):117-24. doi: 10.1038/nchembio.293.

35.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.

Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13.

36.

Functional whole-genome analysis identifies Polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin.

Draghetti C, Salvat C, Zanoguera F, Curchod ML, Vignaud C, Peixoto H, Di Cara A, Fischer D, Dhanabal M, Andreas G, Abderrahim H, Rommel C, Camps M.

J Biol Chem. 2009 Nov 13;284(46):32053-65. doi: 10.1074/jbc.M109.009324. Epub 2009 Aug 21.

37.

Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin.

Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, Ambrogio C, Vilbois F, Chiarle R, Wymann M, Altruda F, Rommel C, Hirsch E.

Eur J Immunol. 2009 Apr;39(4):1136-46. doi: 10.1002/eji.200838884.

38.

Elasticity mapping of pore-suspending native cell membranes.

Lorenz B, Mey I, Steltenkamp S, Fine T, Rommel C, Müller MM, Maiwald A, Wegener J, Steinem C, Janshoff A.

Small. 2009 Apr;5(7):832-8. doi: 10.1002/smll.200800930.

PMID:
19242949
39.

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R.

J Biol Chem. 2009 Apr 24;284(17):11385-95. doi: 10.1074/jbc.M807241200. Epub 2009 Feb 20.

40.

Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits.

Gobert RP, Joubert L, Curchod ML, Salvat C, Foucault I, Jorand-Lebrun C, Lamarine M, Peixoto H, Vignaud C, Frémaux C, Jomotte T, Françon B, Alliod C, Bernasconi L, Abderrahim H, Perrin D, Bombrun A, Zanoguera F, Rommel C, Hooft van Huijsduijnen R.

Mol Cell Biol. 2009 Mar;29(6):1538-53. doi: 10.1128/MCB.01375-08. Epub 2009 Jan 12.

41.

Chemokine receptor CCR2 undergoes transportin1-dependent nuclear translocation.

Favre N, Camps M, Arod C, Chabert C, Rommel C, Pasquali C.

Proteomics. 2008 Nov;8(21):4560-76. doi: 10.1002/pmic.200800211.

PMID:
18846510
42.

Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.

Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E.

Sci Signal. 2008 Sep 9;1(36):ra3. doi: 10.1126/scisignal.1161577.

43.

PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells.

Barbi J, Cummings HE, Lu B, Oghumu S, Rückle T, Rommel C, Lafuse W, Whitacre CC, Satoskar AR.

Blood. 2008 Oct 15;112(8):3048-51. doi: 10.1182/blood-2008-02-135715. Epub 2008 Jul 24.

44.

Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.

Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK, Rommel C, Hirsch E, Arnal JF, Salles JP, Perret B, Breton-Douillon M, Wymann MP, Laffargue M.

Circulation. 2008 Mar 11;117(10):1310-7. doi: 10.1161/CIRCULATIONAHA.107.720466. Epub 2008 Feb 11.

PMID:
18268153
45.

Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo.

Ali K, Camps M, Pearce WP, Ji H, Rückle T, Kuehn N, Pasquali C, Chabert C, Rommel C, Vanhaesebroeck B.

J Immunol. 2008 Feb 15;180(4):2538-44.

46.

Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo.

Pinho V, Russo RC, Amaral FA, de Sousa LP, Barsante MM, de Souza DG, Alves-Filho JC, Cara DC, Hayflick JS, Rommel C, Ruckle T, Rossi AG, Teixeira MM.

J Immunol. 2007 Dec 1;179(11):7891-8. Erratum in: J Immunol. 2008 Jun 1;180(11):7775. de Castro Russo, Remo [corrected to Russo, Remo Castro].

47.

Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth.

Pilecka I, Patrignani C, Pescini R, Curchod ML, Perrin D, Xue Y, Yasenchak J, Clark A, Magnone MC, Zaratin P, Valenzuela D, Rommel C, Hooft van Huijsduijnen R.

J Biol Chem. 2007 Nov 30;282(48):35405-15. Epub 2007 Oct 4.

48.

Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation.

Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W, Hirsch E, Wymann MP, Rückle T, Camps M, Vanhaesebroeck B, Okkenhaug K, Rommel C.

Blood. 2007 Oct 15;110(8):2940-7. Epub 2007 Jul 12.

PMID:
17626838
49.

A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages.

Pasquali C, Bertschy-Meier D, Chabert C, Curchod ML, Arod C, Booth R, Mechtler K, Vilbois F, Xenarios I, Ferguson CG, Prestwich GD, Camps M, Rommel C.

Mol Cell Proteomics. 2007 Nov;6(11):1829-41. Epub 2007 Jul 7.

50.

The chemical composition of animal cells and their intracellular compartments reconstructed from 3D mass spectrometry.

Breitenstein D, Rommel CE, Möllers R, Wegener J, Hagenhoff B.

Angew Chem Int Ed Engl. 2007;46(28):5332-5. No abstract available.

PMID:
17549788

Supplemental Content

Loading ...
Support Center